fp-025
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Dec 1, 2016 (NCT02238834)
Timeline
Indications
Mechanism of action
- Matrix metalloproteinase 12INHIBITOR
MMP12 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- fp-025
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04750278 | Phase 2/Phase 3 (Phase 3) | Apr 6, 2021 | Foresee Pharmaceuticals Co., Ltd. |
| NCT03858686 | Phase 2 | Jul 2, 2018 | Foresee Pharmaceuticals Co., Ltd., QPS, University of Amsterdam |
| NCT03304964 | Phase 1 | Jul 21, 2017 | Foresee Pharmaceuticals Co., Ltd. |
| NCT02238834 | Phase 1 | Dec 1, 2016 | Foresee Pharmaceuticals Co., Ltd., MRA Clinical Research |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Foresee Pharmaceuticals Co., Ltd. | For profit | 4 | 4 | 3 | 2016 |
| MRA Clinical Research | Academic/Hospital | 1 | 0 | 1 | 2016 |
| QPS | For profit | 1 | 0 | 1 | 2018 |
| University of Amsterdam | Academic/Hospital | 1 | 0 | 1 | 2018 |
4 organizations
Page 1 / 1